Skip to main content
Clinical Trials/NCT06700681
NCT06700681
Enrolling By Invitation
Not Applicable

Safety and Efficacy of Remimazolam Compared With Propofol Under EEG DSA Guiding During Cardiac Electrophysiology Studies and Ablation: Randomized Controlled Trial

Taipei Veterans General Hospital, Taiwan1 site in 1 country200 target enrollmentSeptember 20, 2024

Overview

Phase
Not Applicable
Intervention
Propofol
Conditions
Hemodynamic
Sponsor
Taipei Veterans General Hospital, Taiwan
Enrollment
200
Locations
1
Primary Endpoint
Hemodynamic stability--Vasopressor dosage
Status
Enrolling By Invitation
Last Updated
last year

Overview

Brief Summary

Brief Summary:

The goal of this RCT is to compare the Safety and efficacy of remimazolam compared with propofol under EEG DSA guiding during cardiac electrophysiology studies and ablation. The main questions it aims to answer are:

  • Is Remimazolam as efficacy as propofol in cardiac electrophysiology studies and ablation?
  • Is Remimazolam lower hypotension episodes or lower vasopressor dosages compare with propofol in cardiac electrophysiology studies and ablation? If there is a comparison group: Researchers will compare [arm information] to see if [insert effects].

Researchers will compare Remimazolam to Propofol to see if Remimazolam is more feasible in cardiac electrophysiology studies and ablation.

Participants will receive either Remimazolam or Propofol sedation during study period.

Registry
clinicaltrials.gov
Start Date
September 20, 2024
End Date
December 2026
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient receives scheduled cardiac electrophysiology studies and ablation by the same cardiologist(one of the study investigator).

Exclusion Criteria

  • With existing vasopressor or shock status
  • Patient refusal or cannot finish Mini-Cog or QoR-15 preoperatively
  • Canceled by cardiologist
  • Allergy history to the anesthetics used in this study
  • History of abnormal lung function or required oxygen therapy preoperative

Arms & Interventions

TIVA with Propofol and intubation

Patient received cardiac electrophysiology studies and ablation under TIVA with Propofol induction and maintenance and airway is maintained with intubation and controlled ventilation.

Intervention: Propofol

TIVA with Propofol and intubation

Patient received cardiac electrophysiology studies and ablation under TIVA with Propofol induction and maintenance and airway is maintained with intubation and controlled ventilation.

Intervention: With intubation and controlled ventilation to maintain airway

TIVA with Remimazolam and intubation

Patient received cardiac electrophysiology studies and ablation under TIVA with Remimazolam induction and maintenance and airway is maintained with intubation and controlled ventilation.

Intervention: Remimazolam

TIVA with Remimazolam and intubation

Patient received cardiac electrophysiology studies and ablation under TIVA with Remimazolam induction and maintenance and airway is maintained with intubation and controlled ventilation.

Intervention: With intubation and controlled ventilation to maintain airway

TIVA with Propofol and non-Intubated

Patient received cardiac electrophysiology studies and ablation under TIVA with Propofol induction and maintenance and airway is maintained with spontaneous ventilation without intubation(non-intubated).

Intervention: Propofol

TIVA with Propofol and non-Intubated

Patient received cardiac electrophysiology studies and ablation under TIVA with Propofol induction and maintenance and airway is maintained with spontaneous ventilation without intubation(non-intubated).

Intervention: Maintain spontaneous ventilation without intubation

TIVA with Remimazolam and non-Intubated

Patient received cardiac electrophysiology studies and ablation under TIVA with Remimazolam induction and maintenance and airway is maintained with spontaneous ventilation without intubation(non-intubated).

Intervention: Remimazolam

TIVA with Remimazolam and non-Intubated

Patient received cardiac electrophysiology studies and ablation under TIVA with Remimazolam induction and maintenance and airway is maintained with spontaneous ventilation without intubation(non-intubated).

Intervention: Maintain spontaneous ventilation without intubation

Outcomes

Primary Outcomes

Hemodynamic stability--Vasopressor dosage

Time Frame: Introperative

Total dosage of vasopressor used during the procedure

Secondary Outcomes

  • Respiratory depression require intubation(Introperative)
  • TIVA failure rate(Introperative)
  • LOC time(Introperative)
  • Emergence time(Introperative)
  • Sanctification of cardiologist(Perioperative)
  • QoR-15(Preoperative to post-operative day 1)
  • Mini-Cog(Preoperative to post-operative day 1)
  • Length of hospital stay(Upto 1 month)
  • Adverse outcome(Upto 1 month)
  • Length of CU stay(Upto 1 month)

Study Sites (1)

Loading locations...

Similar Trials